CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 40 enrolled
Drug / intervention
Nab-paclitaxel +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01463072
NCT01463072Phase 2Active

Efficacy and Tolerability of Nanoparticle Albumin Bound Paclitaxel (Abraxane) in Patients 65 and Older With Locally Advanced or Metastatic Breast Cancer

City of Hope Medical Center·interventional·Posted Nov 1, 2011·Updated Jul 28, 2025

In Brief

A Phase 2 clinical trial evaluating Laboratory Biomarker Analysis, Nab-paclitaxel, and 1 other intervention for Locally Advanced Breast Carcinoma and 7 related conditions. Active but no longer recruiting, targeting 40 participants across 4 sites.

Detailed Summary

This phase II trial studies the side effects of nab-paclitaxel in treating older patients with breast cancer that has spread from where it started to nearby tissue or lymph nodes (locally advanced) or to other places in the body (metastatic). Drugs used in chemotherapy, such as nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

Study Details

Timeline

Phase 2ActiveOverdue
201220132014201520162017201820192020202120222023202420252026
First PostedNov 1, 2011
Enrollment StartJun 19, 2012
Primary CompletionMay 17, 2017
Study CompletionMay 18, 2026
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 14.7 years ago

Interventions

Laboratory Biomarker Analysisother

Correlative studies

Nab-paclitaxeldrug

Given IV

Questionnaire Administrationother

Ancillary studies